SCYNEXIS Q3 Loss Narrows to $8.5M; $63.2M Cash Funds Operations Into 2029
SCYX is trading near its 52-week low of $3.53 (8.8% above the low) on light trading volume (0.1× avg).
Summary
SCYNEXIS posted a $8.5M Q3 net loss, roughly flat year over year, with $63.2M in cash and investments that management says funds operations into 2029. The BARDA contract of up to $213.9M provides non-dilutive support for SCY-247.
Key Events · Earnings and Guidance · SCYX
-
Q3 Loss Roughly Flat Year Over Year
Net loss was $8.5M, or $0.71 per share, versus $8.6M, or $1.38 per share, in Q3 2025. Nine-month net loss widened to $22.4M from $20.9M.
-
Cash of $63.2M, Runway Into 2029
Cash, cash equivalents and investments totaled $63.2M at September 30, 2026, versus $56.3M at December 31, 2025. Management states capital resources fund operations for at least 12 months and into 2029.
-
R&D Spend Up on Phase 1 Programs
R&D expense rose 14% to $6.2M in Q3, driven by a $1.2M increase for the SCY-247 IV Phase 1 study and $1.3M for the SCY-770 Phase 1 study, partly offset by $1.1M lower MARIO Phase 3 costs.
-
BARDA Contract Up to $213.9M
The September 25, 2026 BARDA contract provides up to $213.9M in non-dilutive funding, with an $18.5M base period to advance SCY-247 into a Phase 2 study; the balance is subject to up to six options over as long as ten years.
Analysis · SCYX · Life Sciences
The quarter itself was steady — net loss of $8.5M versus $8.6M a year ago — but the balance sheet is the story. Cash and investments stood at $63.2M at September 30, down from the $71.1M reported with Q2, and management still says that funds operations into 2029. That runway is what carries the company to the SCY-770 Phase 2 proof-of-concept readout, with trial initiation guided to Q4 2026 and an interim analysis in Q4 2027. The $8.7M warrant fair-value gain that flattered the nine-month loss is non-cash and driven by share-price movement, not operations. The BARDA award of up to $213.9M ($18.5M in the base period) is non-dilutive funding that offsets SCY-247 development costs, reducing the need to raise equity for that program.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SCYX was trading at $3.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.2M. The 52-week trading range was $3.53 to $9.12. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.